Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

1.

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist.

Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling-Hampton K, Appleby M, Brunkow ME, Latham JA.

EMBO J. 2003 Dec 1;22(23):6267-76.

PMID:
14633986
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.

van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Löwik CW.

J Exp Med. 2004 Mar 15;199(6):805-14.

PMID:
15024046
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling.

ten Dijke P, Krause C, de Gorter DJ, Löwik CW, van Bezooijen RL.

J Bone Joint Surg Am. 2008 Feb;90 Suppl 1:31-5. doi: 10.2106/JBJS.G.01183. Review.

PMID:
18292354
[PubMed - indexed for MEDLINE]
4.

Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.

van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P, Löwik CW.

J Bone Miner Res. 2007 Jan;22(1):19-28.

PMID:
17032150
[PubMed - indexed for MEDLINE]
5.

Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells.

Papanicolaou SE, Phipps RJ, Fyhrie DP, Genetos DC.

Biorheology. 2009;46(5):389-99. doi: 10.3233/BIR-2009-0550.

PMID:
19940355
[PubMed - indexed for MEDLINE]
6.

Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis.

Ohyama Y, Nifuji A, Maeda Y, Amagasa T, Noda M.

Endocrinology. 2004 Oct;145(10):4685-92. Epub 2004 Jun 24.

PMID:
15217980
[PubMed - indexed for MEDLINE]
7.

Hedgehog stimulates only osteoblastic differentiation of undifferentiated KS483 cells.

van der Horst G, Farih-Sips H, Löwik CW, Karperien M.

Bone. 2003 Dec;33(6):899-910.

PMID:
14678849
[PubMed - indexed for MEDLINE]
8.

Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.

Kim JY, Lee SK, Jo KJ, Song DY, Lim DM, Park KY, Bonewald LF, Kim BJ.

Life Sci. 2013 Mar 21;92(10):533-40. doi: 10.1016/j.lfs.2013.01.001. Epub 2013 Jan 25.

PMID:
23357248
[PubMed - indexed for MEDLINE]
9.

Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity.

Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, Itoh N.

J Biol Chem. 2003 Jun 27;278(26):24113-7. Epub 2003 Apr 17.

PMID:
12702725
[PubMed - indexed for MEDLINE]
Free Article
10.

Bone morphogenetic proteins and their antagonists: the sclerostin paradigm.

van Bezooijen RL, Papapoulos SE, Löwik CW.

J Endocrinol Invest. 2005;28(8 Suppl):15-7. Review.

PMID:
16323824
[PubMed - indexed for MEDLINE]
11.

Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts.

Sutherland MK, Geoghegan JC, Yu C, Winkler DG, Latham JA.

Bone. 2004 Aug;35(2):448-54.

PMID:
15268896
[PubMed - indexed for MEDLINE]
12.

Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins.

Winkler DG, Sutherland MS, Ojala E, Turcott E, Geoghegan JC, Shpektor D, Skonier JE, Yu C, Latham JA.

J Biol Chem. 2005 Jan 28;280(4):2498-502. Epub 2004 Nov 12.

PMID:
15545262
[PubMed - indexed for MEDLINE]
Free Article
13.

Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation.

Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE, Winkler DG, Latham JA.

Bone. 2004 Oct;35(4):828-35.

PMID:
15454089
[PubMed - indexed for MEDLINE]
14.

DNA methylation contributes to the regulation of sclerostin expression in human osteocytes.

Delgado-Calle J, Sañudo C, Bolado A, Fernández AF, Arozamena J, Pascual-Carra MA, Rodriguez-Rey JC, Fraga MF, Bonewald L, Riancho JA.

J Bone Miner Res. 2012 Apr;27(4):926-37. doi: 10.1002/jbmr.1491.

PMID:
22162201
[PubMed - indexed for MEDLINE]
15.

Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts.

Vincent C, Findlay DM, Welldon KJ, Wijenayaka AR, Zheng TS, Haynes DR, Fazzalari NL, Evdokiou A, Atkins GJ.

J Bone Miner Res. 2009 Aug;24(8):1434-49. doi: 10.1359/jbmr.090305.

PMID:
19292615
[PubMed - indexed for MEDLINE]
16.

Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.

Tu X, Rhee Y, Condon KW, Bivi N, Allen MR, Dwyer D, Stolina M, Turner CH, Robling AG, Plotkin LI, Bellido T.

Bone. 2012 Jan;50(1):209-17. doi: 10.1016/j.bone.2011.10.025. Epub 2011 Oct 30.

PMID:
22075208
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.

Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL.

Endocrinology. 2005 Nov;146(11):4577-83. Epub 2005 Aug 4.

PMID:
16081646
[PubMed - indexed for MEDLINE]
18.

Identification of the disease-causing gene in sclerosteosis--discovery of a novel bone anabolic target?

Balemans W, Van Hul W.

J Musculoskelet Neuronal Interact. 2004 Jun;4(2):139-42. Review.

PMID:
15615113
[PubMed - indexed for MEDLINE]
Free Article
19.

Deletion mutants of BMP folding variants act as BMP antagonists and are efficient inhibitors for heterotopic ossification.

Weber FE, Schmökel H, Oelgeschläger M, Nickel J, Maly FE, Hortschansky P, Grätz KW.

J Bone Miner Res. 2003 Dec;18(12):2142-51.

PMID:
14672349
[PubMed - indexed for MEDLINE]
20.

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.

Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW, Reeve J.

FASEB J. 2005 Nov;19(13):1842-4. Epub 2005 Aug 25.

PMID:
16123173
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk